Form 4: Aquestive Therapeutics Director Julie Krop Acquires Stock Options
SEC Form 4 Filing
Director Julie Krop acquired stock options for 38,000 shares of Aquestive Therapeutics common stock on June 20, 2024.
Summary
- On June 20, 2024, Julie Krop, a director of Aquestive Therapeutics, Inc., acquired stock options for 38,000 shares.
- The exercise price of these options is $2.50.
- The options vest on June 20, 2025, contingent upon Dr. Krop's continuous service with the company.
- The options expire on June 20, 2034.
- Following the transaction, Krop directly owns options for 38,000 shares of Aquestive Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a company director. No inherent positive or negative implications.
Industry Context
This is a standard disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company directors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder confidence due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Julie Krop acquired stock options. |
| 06/20/2025 | Vesting date for 100% of the options, contingent upon continuous service. |
| 06/20/2034 | Expiration date of the stock options. |
| 06/24/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.